Marina Aleksandrovna, Nerseova Tatyana Aleksandrovna, Zhuravleva Anastasia Andreevna, Fedorinov Denis Sergeevich, A. Lyadova, Tatiana A. Nersesova, Anastasia A. Zhuraveva, Denis S. Fedorinov
1Candidate of Medical Sciences, Head of Chemotherapy Department, 2Oncologist of chemotherapeutic department of GBUZ GBKOB, 3Nurse of procedure of chemotherapeutic department of GBUK GKOB, 3Oncologist of the chemotherapeutic department of GBUZ GKOB no.1 department of oncology and palliative medicine.
An open prospective single-center study included patients with various MNDs who were indicated for chemotherapy. Orbis II device was used for prophylactic GCG. The alopecia severity was assessed according to the Common Terminology for Adverse Events (CTCAE) version 5.0 before and during antitumor therapy.
From June 2022 to May 2023 GCG procedures were performed in 51 patients, of which 78% were in patients with TNF of the female reproductive system: breast tumours - 109 (52.2%) sessions, ovarian tumours - 33 (15.8%) cervical tumours - 22 (10.5%). The efficacy of GCG with regard to prevention of severe alopecia gravis was 73%
HGC can be considered as an effective method of alopecia prophylaxis against chemotherapy, Futher studies of wider groups of patients are needed to identify favourable and negative factors influencing the effectiveness of cold helmet.
Alopecia, hair loss, chemotherapy, malignant neoplasms, hypothermia, scalp cooling
